stockrow
Sunday 8 November 2026
Export GRFS’s income statement to Excel — free account
Grifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
8.43
0.03
−0.35%
Follow GRFS
Alert me
Grifols, S.A. (GRFS) EPS (diluted)
Grifols, S.A.'s EPS (diluted) for fiscal 2025 was $0.67, up 168.0% from $0.25 in fiscal 2024. Over the past ten years it has ranged from $0.10 (fiscal 2023) to $1.10 (fiscal 2017); the current reading is higher than 45% of that period. Grifols, S.A. ranks 15th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.67 | 168.00% |
| FY2024 | $0.25 | 150.00% |
| FY2023 | $0.10 | (69.70%) |
| FY2022 | $0.33 | 3.13% |
| FY2021 | $0.32 | (68.93%) |
| FY2020 | $1.03 | 0.98% |
| FY2019 | $1.02 | (0.97%) |
| FY2018 | $1.03 | (6.36%) |
| FY2017 | $1.10 | 23.60% |
| FY2016 | $0.89 | 4.71% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Dec 2025 | $0.16 | (14.58%) |
| Jun 2025 | $0.19 | 850.00% |
| Jun 2024 | $0.02 | (77.78%) |
| Jun 2023 | $0.09 | (11.50%) |
| 21 more quarters | Free account |
Against its own ten years
Low $0.10
High $1.10
Ten-year median
$0.85
Current reading's percentile
45
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BMY Bristol Myers Squibb Company compare | $4.51 |
| NVO Novo Nordisk A/S compare | $3.97 |
| GSK GSK PLC Sponsored ADR compare | $2.98 |
| BIIB Biogen Inc. compare | $2.34 |
| SNY Sanofi compare | $2.02 |
| OGN Organon & Co. compare | $0.76 |
| GRFS Grifols, S.A. | $0.46 |
| AMRN Amarin Corporation PLC compare | −$0.92 |
| NSRX Nasus Pharma Ltd. compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GRFS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement